Comparison of Intraocular Lens Formulas in Patients With Postoperative Refractive Surprise.
Karine D Bojikian1, Dana Lee1, Sarah Lee1
1Ophthalmology, University of Washington, Seattle, USA.
Cureus
|January 2, 2025
Summary
Recent intraocular lens (IOL) formulas show similar accuracy for refractive surprise post-cataract surgery. Shorter eyes are more prone to refractive surprise, suggesting a need for improved biometric analysis in IOL power calculations.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Refractive Surgery
Background:
- Postoperative refractive surprise after phacoemulsification impacts visual outcomes.
- Accurate intraocular lens (IOL) power calculation is crucial for achieving desired refractive targets.
- Identifying factors contributing to refractive surprise is essential for improving surgical predictability.
Purpose of the Study:
- To evaluate the refractive accuracy of eight intraocular lens (IOL) power calculation formulas in eyes experiencing postoperative refractive surprise.
- To determine if newer formulas offer improved refractive outcomes compared to traditional ones in challenging cases.
- To identify risk factors associated with refractive surprise after cataract surgery.
Main Methods:
- Retrospective review of patients undergoing uncomplicated phacoemulsification with refractive surprise (>0.5 D difference).
- Comparison of refractive accuracy using Mean Absolute Error (MAE) and predicted error (PE) for eight IOL power calculation formulas.
- Logistic regression analysis to identify risk factors for refractive surprise, including axial length and biometric ratios.
Main Results:
- 20% of eyes (88/440) met inclusion criteria for refractive surprise (myopic or hyperopic).
- Four newer formulas (Barrett Universal II, RBF 3.0, Kane, LSFAI) showed equivalent accuracy and were superior to older formulas (Hoffer Q, Holladay I/II, SRK/T).
- Shorter axial length was a significant risk factor for both myopic and hyperopic surprise; novel biometric ratios were identified for hyperopic surprise.
Conclusions:
- Four contemporary IOL calculation formulas demonstrated comparable accuracy in eyes with refractive surprise.
- These eyes represent outliers, with no single formula consistently providing superior refractive outcomes.
- Shorter axial length is a key risk factor, and further investigation into novel biometric parameters is warranted to enhance refractive predictability.
Related Concept Videos
01:16Focusing of Light in the Eye
1.5K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
1.5K
01:28Angle Closure Glaucoma: Treatment
360
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
360
01:27Open Angle Glaucoma: Treatment
355
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
355